Crescent Biopharma, Inc. (CBIO) scores 48 out of 100 on boothcheck's 11-model valuation framework. Verdict: Avoid The estimated fair value is $2.24, representing a 79% premium to fair value. Quantitative score: 63/100. Qualitative score: 30/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.